Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up study of females previously exposed to eleclazine
NL-OMON56367Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of eleclazine, sponsored by Gilead Sciences. Primary endpoints: Number of females enrolled and Number of females with signs or symptoms potentially consistent with uterine cancer after eleclazine exposure. Started Sep 2023; status: active, not recruiting.
02
Drugs
eleclazine
Beyond the preview
Go deeper on NL-OMON56367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56367.